Today American pharmaceutical company Bristol Myers Squibb (BMS) announces that it has selected Leiden Bio Science Park as the European site for a new CAR-T cell therapy facility. With this, the biopharmaceutical company is taking advantage of the growing life sciences region in the Netherlands.
The company will manufacture and develop CAR T-cell therapy for patients with blood cancer (leukaemia), for example. However, the company will not only bring knowledge development and therapies to the Leiden region but will also create an expected 500 new jobs.
To read more, please click here.
